Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation (Q39609067)

13 September 2017

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation (English)

1 reference

13 September 2017

Dario Neri

4

0 references

author name string

Katharina Frey

series ordinal

1

1 reference

PubMed ID

21225052

13 September 2017

Andjelija Zivanovic

series ordinal

2

1 reference

PubMed ID

21225052

13 September 2017

Kathrin Schwager

series ordinal

3

1 reference

13 September 2017

11 January 2011

1 reference

13 September 2017

1 reference

13 September 2017

3

1 reference

13 September 2017

468-478

1 reference

13 September 2017

4

1 reference

Interferons at age 50: past, current and future impact on biomedicine

13 September 2017

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Type I interferons (alpha/beta) in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Interferons, interferon-like cytokines, and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Characterization of the murine alpha interferon gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

IFN-alpha and novel strategies of combination therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Interferons alpha and beta as immune regulators--a new look

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Interferons, immunity and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Next generation of immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Selective targeted delivery of TNFalpha to tumor blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

New insights into form and function of fibronectin splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

A Human mAb Specific to Oncofetal Fibronectin Selectively Targets Chronic Skin Inflammation In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0IB00099J

21 January 2018

Identifiers

DOI

10.1039/C0IB00099J

1 reference

13 September 2017

1 reference

PubMed ID

21225052